ArticleCureus2025
Tumor Lysis Syndrome in an Elderly Male With Newly Diagnosed Large Cell B-Lymphoma Despite Prophylactic Treatment.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor lysis syndrome (TLS) is a life-threatening complication that can arise after initiation of cytotoxic chemotherapy in highly proliferative hematological malignancies, such as leukemias or lymphomas. Prophylactic measures, such as allopurinol, rasburicase, and hydration, are commonly initiated in these types of malignancies prior to chemotherapy to prevent TLS. However, in rare instances, TLS can still occur despite the initiation of prophylactic treatment. When TLS develops, the patient can experience various complications, such as kidney injury, muscle fatigue, paralysis, cardiac arrhythmias, and even death. Our case presents an 83-year-old male with newly diagnosed stage IV diffuse large B-cell lymphoma (DLBCL) who developed TLS following chemotherapy despite receiving the standard prophylactic treatment of IV fluids, rasburicase, and allopurinol. This case highlights the importance of identifying signs of TLS and initiating appropriate treatment even in patients receiving prophylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.